|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000034721 |
|
最近更新日期: Date of Last Refreshed on: |
2020-07-18 21:44:11 |
|
注册时间: Date of Registration: |
2020-07-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
审核中(四)阴道微生态对胎膜早破的预警作用 |
|
Public title: |
Early warning of vaginal microecology on premature rupture of membranes |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
亚精胺在预防胎膜早破中的预警机制研究 |
|
Scientific title: |
Early warning mechanism of spermidine in prevention of premature rupture of membranes |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈道桢 |
研究负责人: |
陈道桢 |
|
Applicant: |
Chen Daozhen |
Study leader: |
Chen Daozhen |
|
申请注册联系人电话: Applicant telephone: |
+86 510-82725161 |
研究负责人电话: Study leader's telephone: |
+86 510-82725161 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chendaozhen@163.com |
研究负责人电子邮件: Study leader's E-mail: |
chendaozhen@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省无锡市梁溪区槐树巷48号 |
研究负责人通讯地址: |
江苏省无锡市梁溪区槐树巷48号 |
|
Applicant address: |
48 Huaishu Lane, Liangxi District, Wuxi, Jiangsu, China |
Study leader's address: |
48 Huaishu Lane, Liangxi District, Wuxi, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学附属无锡妇幼保健院 |
||
|
Applicant's institution: |
The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University |
||
|
研究负责人所在单位: |
南京医科大学附属无锡妇幼保健院 |
||
|
Affiliation of the Leader: |
The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020-01-0429-14 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
无锡市妇幼保健院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-05-07 00:00:00 |
||
|
伦理委员会联系人: |
蒋洁 |
||
|
Contact Name of the ethic committee: |
Jiang Jie |
||
|
伦理委员会联系地址: |
江苏省无锡市梁溪区槐树巷48号 |
||
|
Contact Address of the ethic committee: |
48 Huaishu Lane, Liangxi District, Wuxi, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
南京医科大学附属无锡妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省无锡市梁溪区槐树巷48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
48 Huaishu Lane, Liangxi District, Wuxi, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
阴道微生态规范化诊疗在宫颈癌早期预警及干预中的推广示范应用(N20192004) |
||||||||||||||||||||||
|
Source(s) of funding: |
Developement & Demonstration Program of WuXi (N20192004) |
||||||||||||||||||||||
|
Target disease: |
premature rupture of membranes |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
阐明阴道微生态失衡对胎膜早破的预警作用,进行早期调节干预,使孕期阴道微生态保持正常,减少胎膜早破引起的妊娠不良结局。检测并寻找阴道微生态失衡的特异性代谢产物,为临床早期预防和精准治疗提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Objective to clarify the early warning effect of vaginal microecology imbalance on premature rupture of membranes (PROM), and carry out early regulatory intervention to keep the vaginal microecology normal during pregnancy and reduce the adverse pregnancy outcomes caused by premature rupture of membranes. To detect and search for the specific metabolites of vaginal microecological imbalance, so as to provide the basis for clinical early prevention and accurate treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入定期产检的单胎头位孕妇。 |
||||||||||||||||||||||
|
Inclusion criteria |
Pregnant women with single head position were included in the regular prenatal examination. |
||||||||||||||||||||||
|
排除标准: |
除阴道炎症以外引起胎膜早破的高危因素或可能干扰检测结果:孕妇有阴道出血、创伤、宫颈机能不全、全身感染性疾病、自身免疫性疾病、严重的内外科合并症,48小时内有阴道消毒或用药。 |
||||||||||||||||||||||
|
Exclusion criteria: |
In addition to vaginitis, the high-risk factors causing premature rupture of membranes or possible interference test results: pregnant women have vaginal bleeding, trauma, cervical dysfunction, systemic infectious diseases, autoimmune diseases, serious internal and external complications, vaginal detoxification or medication within 48 hours. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-07-20 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-07-20 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用。入选妊娠孕妇,根据妊娠结局分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A. Pregnant women were selected and grouped according to pregnancy outcome. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用临床试验公共管理平台ResMan向公众开放查询, http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data will be published in the public management platform of clinical trials ResMan after the Study Completed 6 months, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |